


Curriculum vitae

Dr. med. Livius Penter Forum 4, Raum 1.0523 Augustenburger Platz 1 13353 Berlin Germany	+49 (0)30 450 553 615 Livius.Penter@charite.de  0000-0002-9060-0207	Born October 02, 1987 in Dresden, Germany Married www.penterlab.org
--	--	---



Research

Since 10/2023	Charité – Universitätsmedizin Berlin, Germany Max-Eder Research Group leader <i>Cancer and immune cell co-evolution</i>
10/2019 – 09/2023	Dana-Farber Cancer Institute, USA Postdoctoral research fellow (Wu Lab) <i>CTLA-4 blockade for relapsed myeloid malignancies after transplantation</i>
06/2015 – 09/2019	Charité – Universitätsmedizin Berlin, Germany Postdoctoral research fellow (Hansmann Lab) <i>Immunologic biomarkers and therapeutic targets in rectal cancer</i>
08/2009 – 05/2015	Laboratory of Pediatric Molecular Biology Berlin, Germany Medical thesis (Prof. Hagemeier) <i>Development of a lentiviral shRNA screen in SH-EP neuroblastoma cells</i>
06 – 08/2013	Research Institute of Molecular Pathology Vienna, Austria Vienna Biocenter Summer School (Zuber Lab)
09/2005 – 06/2007	Max Planck Institute of Molecular Cell Biology Dresden, Germany School project: <i>Phylogenetic analysis of proteins using bioinformatics tools</i>

Education

Since 10/2023	Berlin Institute of Health Digital Clinician Scientist
07/2016 – 07/2018	Berlin Institute of Health Junior Clinician Scientist
01/2015 – 09/2019	Charité – Universitätsmedizin Berlin Internal Medicine and Hematology/Oncology
05/2015	Medical thesis with grade 1.0 (magna cum laude)
11/2014	Medical state examination with grade 1.33 (1.0=best, 5.0=bottom)
06/2007	Martin-Andersen-Nexö-Gymnasium Dresden, Germany High school diploma with grade 1.0 (1.0=best, 6.0=bottom) <i>Prizes in informatics competitions and work as administrator of computer pool</i>

International experience

	McGill University Montreal, Canada
02 – 04/2014	Clinical electives in cardiology and nephrology
	Université Diderot Paris VII, France
09/2013 – 02/2014	Clinical electives in general surgery and medical oncology
	Université Pierre et Marie Curie Paris VI, France
08/2011 – 06/2012	ERASMUS exchange
	Bangalore Baptist Hospital, India
02 – 03/2010	Clinical elective in general surgery
	Morrin High School, Alberta, Canada
09/2004 – 06/2005	High school diploma

Scholarships and awards

Since 10/2023	Berlin Institute of Health – Digital Clinician Scientist Grant
01 – 06/2023	EHA-EMBL/EBI Computational Biology Training in Hematology (CBTH)
07/2022	ASH Scholar Award
12/2020 and 12/2021	ASH Achievement Award
10/2019 – 03/2022	German Research Foundation (DFG) – Research Fellowship
07/2016 – 06/2018	Berlin Institute of Health – Junior Clinician Scientist Grant
09/2013 – 04/2014	German Academic Exchange Service (DAAD) – Exchange Scholarship
08/2013	Vienna Biocenter – VWR Summer School Prize
05/2010 – 11/2014	German Academic Scholarship Foundation – University Scholarship

Languages spoken

German	native
English	near-native (C2)
French	proficient (C1)
Romanian	proficient (C1)

Selected Publications

Dana-Farber Cancer Institute (2019 – 2023)

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ

Blood. 2023 Apr 13;141(15):1817-1830. **IF 20.3**

Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models

Penter L*, ten Hacken E*, Southard J, Lareau CA, Ludwig LS, Li S, Neuberg DS, Livak KJ, Wu CJ

Cancer Research. 2023 Mar 2;83(5):667-672. **IF 11.2**

AML relapse after a TIGIT race

Penter L, Wu CJ

Blood. 2022 Sep 15;140(11):1189-1191. **IF 20.3**

Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics

Penter L, Gohil SH, Wu CJ

Frontiers in Immunology. 2022 12:788891. **IF 8.8**

Coevolving JAK2V617F⁺ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case

Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg DS, Hodi FS, Livak KJ, Zeiser R, Bachireddy P, Wu CJ

Blood Advances. 2021 5(22):4701-4709. **IF 7.6**

Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history

Penter L*, Gohil SH*, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ.

Cancer Discovery. 10.1158/2159-8290.CD-21-0276. 2021 **IF 38.3**

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ.

Blood. 2021 137 (23), 3212-3217. **IF 25.5**

Personal tumor antigens in blood malignancies: genomics-directed identification and targeting

Penter L, Wu CJ

JCI. 2020 130 (4), 1595-1607. **IF 14.8**

Charité – Universitätsmedizin Berlin (2015 – 2019)

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer

Penter L, Dietze K, Ritter J, Lammoglia-Cobo MF, Garmshausen J, Aigner F, Bullinger L, Hackstein H, Wienzek-Lischka S, Blankenstein T, Hummel M, Dornmair K, Hansmann L.

Oncolimmunology. 2019 8 (6), e1586409. **IF 5.9**

FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells

Penter L, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.

Eur J Immunol. 2018 Jul;48(7):1248-1250. **IF 4.7**

A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma

Penter L, Maier B, Frede U, Hackner B, Carell T, Hagemeier C, Truss M.

Target Oncol. 2015 Dec;10(4):523-33. **IF 2.9**